On 4/10/2017, Shares of Lannett Co Inc (NYSE:LCI) closed at $26.10 in last trading day. After noting the initial trading entry at $23.70, it reached to a day’s high of $27.30 and moved to a day’s low of $23.65. The recent daily volume was 2.22 million as contrast to it’s an average volume of 979.47 thousand.
The last close of the Lannett Co Inc stock reflects that it traded up +18.07% from its 50-day moving average of $22.11. The stock traded above +15.93% to its 200-day MA of $22.51. Furthermore, it moved lower -34.73% from its 52-week high of $39.99 and +55.82% up from $16.75, which is 52-week low of the stock.
Lannett Company, Inc.’s (LCI) moved with shift of 21.96% in the past week. Over the last three months, the shares of the company have changed 16.52% and performed 1.99% over the last six months. The stock currently has Monthly Volatility of 4.93% and Weekly Volatility of 6.91%.
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. The company provides its products for various medical indications comprising glaucoma, muscle relaxant, migraine, anesthetic, congestive heart failure, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, dryness of the mouth, gout, hypertension, and gallstone. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Lanoxin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Salagen, Dyazide, and Actigall brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.
Endologix, Inc. (NASDAQ:ELGX) finalized the last transaction at value of $6.50, with a daily change of -2.26% or -0.15 points. The company maintained volume of 736.24 thousand shares. In past trading day, the stock hit the maximum price of $6.70 and touched to minimum value of $6.50. It has a market cap of $ 539.01M.
As of last trade close, the stock is trading downside -55.16% from its one year high of $14.49 and moved +35.98% upward from $4.78, which is one year low of the stock.
The stock traded below -3.49% from its 50-day moving average of $6.74. Furthermore, the stock moved -19.35% to its 200-day MA of $ 8.06.
Endologix, Inc.’s (ELGX) moved with shift of -9.47% in the past week. Over the last three months, the shares of the company have changed 7.97% and performed -49.49% over the last six months. The stock currently has Monthly Volatility of 4.48% and Weekly Volatility of 5.22%.
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patient’s anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.